Study Title and Description
Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation.
Key Questions Addressed
|3||In adult renal transplants, how do immunosuppressive regimens designed to reduce or eliminate exposure to CNI toxicity compare with each other and with full-dose CNI regimens for health outcomes? AND How does the type of induction agent (including when no induction is used) and the use of concurrent immunosuppressive agents affect outcomes of regimens that reduce or eliminate CNI exposure?|
Primary Publication Information
|Title||Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation.|
|Author||Langer RM., Hené R., Vitko S., Christiaans M., Tedesco-Silva H., Ciechanowski K., Cassuto E., Rostaing L., Vilatoba M., Machein U., Ulbricht B., Junge G., Dong G., Pascual J.|
|Country||Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary. firstname.lastname@example.org|
Pubmed ID: 22471345
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Comparative Effectiveness of Regimens
Results & Comparisons
No Results found.